BioCentury
ARTICLE | Company News

Immunocore, Lilly in cancer immunotherapy deal

July 17, 2014 12:55 AM UTC

Immunocore Ltd. (Abingdon, U.K.) partnered with Eli Lilly and Co. (NYSE:LLY) to use Immunocure's ImmTAC technology to discover and develop ImmTACs against three undisclosed jointly selected targets for cancer. ImmTACs are bispecific molecules consisting of a soluble monoclonal T cell receptor (mTCR) fused to an anti-CD3 antibody fragment that recruits T cells to the tumor. Immunocore will receive $15 million in cash up front per target program to generate preclinical candidate packages. For each program Lilly chooses to develop further, Immunocore will receive an opt-in fee of $10 million and an option to continue co-development on a cost-sharing and profit-sharing basis. If Immunocore does not exercise the option, the company will be eligible for undisclosed milestones, plus royalties. ...